Company Product Description Indication Status
Phase I
Affiris AG, of Vienna PD-01 Synuclein alpha inhibitor Parkinson's disease Results of treating early PD, published in Lancet Neurology showed repeated immunization with PD-01A was safe and well-tolerated over extended period and led to positive antibody response specific for alpha-synuclein 
Heat Biologics Inc., of Durham, N.C. PTX-35 T-cell co-stimulator targeting TNFRSF25 (death receptor 3) Solid tumor Initiated first clinical trial site
Innovent Biologics Inc., of Suzhou, China, and Eli Lilly and Co., of Indianapolis IBI-362 Dual GLP-1R and GCGR agonist Obesity  First subject dosed in phase Ib/II  trial in China
Lineage Cell Therapeutics Inc., of Carlsbad, Calif. Opregen Retinal pigment epithelium cell transplant therapy Dry age-related macular degeneration Restarted patient enrollment in phase I/IIa study
Pfizer Inc., of New York, and Sangamo Therapeutics Inc., of Brisbane, Calif. Giroctocogene fitelparvovec (SB-525; PF-07055480) Adeno-associated virus-based gene therapy Hemophilia A Updated phase I/II data showed all 5 patients with severe hemophilia A who received 3e13 vg/kg dose showed sustained FVIII activity levels, with a median of 64.2% via chromogenic assay; none experienced bleeding events or required FVIII infusions
Seattle Genetics Inc., of Bothell, Wash. SGN-TGT Anti-TIGIT antibody Lymphoma; solid tumor Dosed first patient
Seattle Genetics Inc., of Bothell, Wash. SGN-B6A ADC targeting integrin beta-6 Solid tumor Dosed first patient
Phase II
Aptinyx Inc., of Evanston, Ill. NYX-783 NMDA receptor modulator Post-traumatic stress disorder Completed enrollment in the study testing the change in Clinician-Administered PTSD Scale for the DSM-5 total score and subscores after 4 weeks; data expected in late 2020
Aribio Co. Ltd., of Seongnam, South Korea AR-1001 Multitarget drug to remove beta-amyloid oligomers in circulation, inhibit neuronal cell death and restore synaptic loss  Mild to moderate Alzheimer’s disease Completed enrollment in the 210-patient study; top-line results expected by early 2021
Eloxx Pharmaceuticals Inc., of Waltham, Mass. ELX-02 CFTR gene modulator; ribosomal protein modulator Cystic fibrosis Resumed enrollment at sites in Israel and Europe after being temporarily paused due to COVID-19 pandemic
Xeris Pharmaceuticals Inc., of Chicago XP-3924  Amylin analogue pramlintide plus insulin Type 1 diabetes mellitus XP-3924 produced a 62.3% reduction of hyperglycemia after a glucose challenge compared to Humulin R (insulin) (p<0.001); postprandial glycemic control for XP-3924 was comparable to co-administered injections of Humulin R and Symlin (pramlintide)
Phase III
Abbvie Inc., of North Chicago Rinvoq (upadacitinib) JAK inhibitor Atopic dermatitis In the Measure Up 1 study, 70% and 80% of patients taking the 15-mg and 30-mg doses, respectively, had at least a 75% improvement in the Eczema Area Severity Index compared to 16% of patients taking placebo; 48% and 62% of patients taking the 2 respective doses had an Investigator's Global Assessment for Atopic Dermatitis of clear or almost clear compared to 8% of patients taking placebo 
Adamas Pharmaceuticals Inc., of Emeryville, Calif. Gocovri (amantadine) Reduces the amount of glutamate hyperactivity   Multiple sclerosis with walking impairment Doesn't plan to continue phase III development for the indication
Genentech Inc., a unit of Basel, Switzerland-based Roche Holding AG Tecentriq (atezolizumab) Monoclonal antibody targeting PD-L1 Early triple-negative breast cancer, regardless of PD-L1 expression In the Impassion031 study, Tecentriq plus Abraxane (albumin-bound paclitaxel, Bristol Myers Squibb Co.) produced a statistically significant and clinically meaningful improvement in pathological complete response; data to be presented at an upcoming medical meeting
Hua Medicine Ltd., of Shanghai Dorzagliatin Glucokinase stimulator Type 2 diabetes In the Seed study, dorzagliatin reduced HbA1c by 1.15 percentage points compared to a reduction of 0.58 percentage points for placebo; all patients were then given dorzagliatin in the open-label period for an additional 28 weeks; at 52 weeks, HbA1c reduction was 1.11 for dorzagliatin and 1.27 for the patients switched from placebo to drug
Teva Pharmaceutical Industries Ltd., of Tel Aviv, Israel Ajovy (fremanezumab-vfrm) Monoclonal antibody targeting CGRP Migraine A post-hoc analysis of pooled studies found 71% and 70% of patients with a baseline MIDAS score of 11-20 treated quarterly and monthly, respectively, with Ajovy had a 5-point reduction from their baseline in the MIDAS score compared to 49% of patients treated with placebo; for patients with a MIDAS score of >20, 69% and 79% of patients treated quarterly and monthly, respectively, with Ajovy had a ≥30% reduction in points compared to 58% of patients taking placebo; 53% and 55% of patients treated quarterly and monthly, respectively, with Ajovy had a 5-point reduction from baseline in HIT-6 scores compared to 39% of patients taking placebo

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments